Related Experiment Video
Updated: May 6, 2026
07:18
A Behavioral Test Battery for the Repeated Assessment of Motor Skills, Mood, and Cognition in Mice
Published on: March 2, 2019
19.0K
Mild Behavioral Impairment and cognitive functions: A systematic review and meta-analysis
Barbara Blasutto1, Francesco Fattapposta2, Maria Casagrande3
1Department of Psychology, University of Rome "Sapienza", Rome 00185, Italy.
Ageing Research Reviews
|January 28, 2025
Summary
Mild behavioral impairment (MBI) involves behavioral changes linked to cognitive decline. This review found MBI symptoms correlate with poorer performance in memory and executive functions, suggesting early neurodegeneration detection.
Area of Science:
- Neuroscience
- Gerontology
- Psychiatry
Background:
- Mild behavioral impairment (MBI) is a new concept describing behavioral changes in late life.
- The link between MBI and cognitive decline requires further clarification.
- MBI may indicate early neurodegenerative processes.
Purpose of the Study:
- To systematically review and meta-analyze the relationship between MBI and cognitive functioning.
- To explore MBI's role as a potential early indicator of neurodegeneration.
Main Methods:
- Systematic review and meta-analysis following PRISMA guidelines.
- Included peer-reviewed studies measuring MBI and cognitive function.
- Excluded studies on neurological disorders, dementia, psychiatric disorders, neuroimaging, or genetics.
Main Results:
- Individuals with MBI showed significantly worse cognitive performance compared to controls.
- Deficits were most pronounced in memory and executive functions.
- Qualitative and quantitative analyses supported these findings.
Conclusions:
- MBI symptoms are associated with cognitive impairment, particularly in memory and executive functions.
- MBI may serve as an early marker for neurodegenerative diseases.
- Comprehensive behavioral and cognitive assessments are crucial for early detection and intervention.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
926
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
926
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:30Cognitive Development During Adulthood
1.4K
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.4K